+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
ID07366099

Using Al18F-NOTA-LM3 and 68Ga-DOTATATE PETCT Scans to Diagnose and Evaluate Tumor-Induced Osteomalacia in Adults

Led by Peking Union Medical College Hospital · Updated on 2026-01-26

40

Participants Needed

1

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Tumor-induced osteomalacia TIO is a rare condition caused by tumors that affect bone health. This research aims to evaluate the use of a new PETCT imaging tracer called Al18F-NOTA-LM3 to locate tumors responsible for TIO. The study compares this tracer with the commonly used 68Ga-DOTATATE to see which one better detects the tumors, including small ones that may be missed by other imaging methods. Participants will receive two different PETCT scans one using the Al18F-NOTA-LM3 tracer and another using 68Ga-DOTATATE. For the Al18F-NOTA-LM3 scan, the tracer is injected and the whole-body scan is done 60 to 120 minutes later. For the 68Ga-DOTATATE scan, the injection is followed by a scan 40 to 60 minutes afterward. Both scans aim to identify tumor locations in the same group of patients. During the study, participants will undergo these imaging procedures and be monitored for how well each tracer detects tumors. Researchers will measure the diagnostic value of the scans and compare standardized uptake values SUV of the tumors. The study period includes follow-up to six months after completion. This comprehensive evaluation helps determine which imaging method may be more useful for diagnosing TIO.

CONDITIONS

Brief Title

Al18F-NOTA-LM3 PET/CT in Patients With TIO

Research Team

H

Hongli Jing

Y

Yuwei Zhang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here